gs-7340 and Neoplasms

gs-7340 has been researched along with Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for gs-7340 and Neoplasms

ArticleYear
Efficacy and Renal Safety of Prophylactic Tenofovir Alafenamide for HBV-Infected Cancer Patients Undergoing Chemotherapy.
    International journal of molecular sciences, 2022, Sep-26, Volume: 23, Issue:19

    There are no data comparing the efficacy and safety of prophylactic entecavir (ETV), tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) for HBV-infected cancer patients undergoing chemotherapy. This study aimed to compare the efficacy and renal safety of ETV, TDF and TAF in this setting. HBsAg-positive cancer patients treated with ETV (n = 582), TDF (n = 200) and TAF (n = 188) during chemotherapy were retrospectively enrolled. Antiviral efficacy and risk of renal events were evaluated. The rate of complete viral suppression at 1 year was 94.7%, 94.7% and 96.1% in ETV, TDF and TAF groups, respectively (

    Topics: Acute Kidney Injury; Adenine; Alanine; Antiviral Agents; Cisplatin; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Kidney; Neoplasms; Retrospective Studies; Tenofovir; Treatment Outcome

2022